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SUMMARY.-Five injections ofurethane, 1 mg./g. body weight to suckling mice
markedly reduced the primary immune response against sheep red blood cells
assessed by splenic plaque forming cells (PFC) determination and haemagglu-
tinin (HA) titration. The immunological impairment lasted for about 50 days
after the end of the treatment. The secondary response tested by HA titration
was not affected. A lower dose of urethane (0-5 mg./g.) produced only a delay
of the primary HA response. A single neonatal dose of N-nitrosomethylurea
(NMU) caused a profound immunodepressionevaluated as HAtitre and number
of PFC. Both primary and secondary responses were still depressed when
tested at 50 and 90 days of age respectively. No clear correlation between the
degree ofimmunodepression and lymphoma development was found.
THE existence of tumour specific antigens on neoplastic cells is now well
established in many experimental systems. Therefore, the immunological appara-
tus should exert an important role in controlling the development of neoplasia
and any interference with immune functions should influence the incidence and
latency of tumours as originally proposed by Prehn and Main (1957). This
hypothesis has been proved by several studies in mice which included the role of
thymectomy on chemical- and virus-induced tumours (Miller et al., 1963; Law,
1966) and the contribution of the immunodepressive effect of carcinogenic sub-
stances totheir own carcinogenic action (Prehn, 1963; Stjernsward, 1967). Among
the chemical carcinogens, the polycyclic hydrocarbons have been shown to reduce
both humoral and cell-mediated immune responses (Stjernsward, 1969), while
other classes of chemical carcinogens have been little investigated from this point
of view.
In this report, studies dealing with the effect of two carcinogenic compounds,
ethylcarbamate (urethane) and N-nitrosomethylurea (NMU), on the immune
response of mice will be presented. Both chemicals are water-soluble and break
down rapidly in the animal body (Kaye, 1960; Magee and Barnes, 1967), thereby
providing a suitable experimental model to test their action on immunity after
their complete elimination from the tissues. Both these compounds have been
shown to induce several types of tumours including lymphosarcomas. Whereas
NMU can do so after a single neonatal dose (Graffi and Hoffmann, 1966; Terracini
and Stramignoni, 1967; Terracini and Testa, 1970), urethane must be administered
more than once to suckling mice (Vesselinovitch and Mihailovich, 1966; Della
Porta et al., 1967). In fact, when given as a single neonatal dose, urethane elicits
only few or no lymphomas but a high incidence of lung adenomas in Swiss mice
and hepatomas in C3Hfmice (Chieco-Bianchi et al., 1963; Klein, 1966).IMMUNODEPRESSION DURING URETHANE LEUKAEMOGENESIS
Although the immunodepressive effect of urethane was already demonstrated
in 1952 by Malmgren, Bennison and McKinley, only recently urethane carcino-
genicity hasbeen studied inrelation to its action on the immune system. Previous
work from this and other laboratories showed that carcinogenic doses of urethane
clearly reduced the immune response either humoral (Haran-Ghera and Peled,
1967; Parmiani et al., 1969) or cell-mediated (Lappe and Steinmuller, 1970;
Parmiani, 1970). The depression of humoral and of cell-mediated immunity was
also found to be correlated respectively with the development ofleukaemia and of
lung adenomas (Parmiani et al., 1969; Lapp6 and Prehn, 1970).
No reports concerning the effects of NMU on the immune functions are
available.
In the case of urethane, the aims of the present study were to confirm the
immunodepressive effect of urethane on antibody production at cellular level, to
verify the duration of the impairment of the primary response and to investigate
the relationship between dosage and immunosuppressive action.
In the experiment with NMU, mice were exposed to a single neonatal dose and
their immunological 8tatus evaluated through the haemagglutinin response
against sheep red blood cells and the formation of plaque-forming cells in the
spleen.
In both experimental groups an attempt was made to establish a correlation
between the degree ofimmune deficit and lymphoma yield or latency. A similar
evaluation for other types of neoplasm was made impossible by the concurrent
presence ofdifferent kind oftumours in the same animals and bythe small number
of animals which remained free of tumours.
MATERIALS AND METHODS
Animal6.-C3Hf/Dp and SWR/Dp inbred mice ofboth sexes were used. They
were maintained in plastic cages, with tap water and commercial diet in pellets
(Mangimi Valle Olona, Castellanza, Italy) ad libitum.
Chemicals.-Urethane (Merck A. G., Darmstad) was dissolved in distilled
sterile water in 6% solution and immediately injected intraperitoneally. The
treatment consisted of five injections, at 2 days interval, of 0 5 or 1 mg./g. body
weight starting at 10 days of age. Control mice were kept untreated. Recrys-
talized N-nitrosomethylurea (NMU) was obtained through the courtesy of Mr.
P. F. Swann, Courtauld Institute of Biochemistry, Middlesex Hospital Medical
School, London. It was dissolved in saline immediately before use at a concen-
tration of 0.1%. Injections were given intraperitoneally at the dose of 25 or
50 ,tg./g. body weight, within 24 hours from birth. Control animals received a
corresponding volume of saline.
Immunization procedures.-Sheep red blood cells (SRBC) were washed three
times in saline and injected intraperitoneally as 5% suspension (v/v) in 0-25 ml.
of saline.
Haemagglutinin determination.-Mice were bled from the retro-orbital plexus.
Inactivated sera were diluted in phosphate buffered saline pH 7-2 and serial
two-fold dilutions were prepared in Takatsy plastic type plates, the first well
contining 0 1 ml. ofeither 1: 10 or 1: 4 diluted antiserum. To each well 0 1 ml.
of three times washed 0.5% SRBC was added; haemagglutinin (HA) titres were
read after the suspension had settled for 4 hours at room temperature and were
controlled after a night.
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Plaque-forming cells determination. The number ofplaque forming cells (PFC)
in the spleen was determined following the technique of Jerne et al. (1963). Four
days after immunization the spleen was surgically removed under nembutal
anaesthesia and weighed. The nucleated cells of each spleen (NSC) were counted
and then processed for PFC determination in agar plates. Three plates were
prepared from each spleen, and the number ofPFC was calculated as a mean ofthe
three plates.
Pathology. Mice were killed when they showed clear symptoms of lymphoma.
All survivors were killed at 60-65 weeks of age. Complete autopsy was performed
on all animals and specimens were fixed in Bouin, embedded in paraffin and stained
with haematoxylin and eosin.
Statistics. Analysis of the results was made by the " t " test. The results
were considered statistically significant when P < 0 01.
RESULTS
Urethane
Experiment 1.-A group of 19 male and 27 female C3Hf mice admiiiistered
five injections of urethane 1 mg./g. body weight from the 10th to the 18th day of
age and a group of 14 male and 13 female untreated controls were immunized
with SRBC at 31 days of age. Four additional groups of 6-14 urethane-treated
and control mice were immunized at 46, 61, 76and 91 daysofagerespectively. The
number ofPFC was determined 4 days after the immunization.
TABLE I. Effect ofFive Doses of Urethane Administered During Infancy to
C3Hf Mice on Plaque-Forming Spleen Cells
PFC/106 No. nucleated Spleen
Age at nucleated cells/spleen weights Body weight
test No. of spleen cells x 106 (mg.) (g.)
Groups (days) mice (mean + S.E.) (mean ± S.E.) (mean ± S.E.) (mean + S.E.)
Controls 35 27 476±72 . 89±7 12315 17-3±0-3
Urethane 46 42±5* 50±5* 89±6* . 111±0.8*
Controls 50 14 605±68 112±8 119±5 . 20-0±0-5
Urethane 10 132±24* 88±9t . 139±10t 18-3±1-Ot
Controls 65 7 321±42 . 76±7 121±4 21-2±0-3
Urethane 10 395±83t 66±6t 122±7t 20-2±2-3t
Controls 80 6 386± 60 921 8 125± 7 22- 1±1-2
Urethane 10 700± 107t 124 4t 135±4t 20-4±0-2t
Controls 95 14 1194±204 150±12 140±5 . 25 5±0 8
Urethane 9 727± 95t 125 4-16t 102± 8t . 21-9±09*
*P < 0001.
t Not significant (P > 0 01).
The results are presented in Table I. At 35 days ofage the number ofPFC/106
NSC was ten-fold lower in the urethane-treated mice than in the controls. The
immunological impairment was still present at 50 days of age, whereas at 65 days
and thereafter the number of PFC did not appear to be significantly diffelent
from that of the control groups. Spleen weight, NSC, and body weight oftreated
animals were markedly reduced in comparison to controls at 35 days only.
The group tested for PFC at 35 days of age, was kept under observation for
tumour development for 60 weeks. Six lymphosarcomas appeared among the
13 males and 21 females surviving after splenectomy. As reported in Table II,
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TABLE II.-Relationship Between Development of Thymic Lymphosarcoma and
Number ofPlaque-Forming Cells at 35 Days in Urethane-treated C3Hf Mice
PFC/106
nucleated
Number spleen cells
Groups Sex of mice (mean ± S.E.)
Ly mice . . ? . 4 . 22±6
Non ty mice . . 17 53±8*
Ly mice . . 2 . (15) (87)
Non Ly mice . . 11 . 48±17
Ly mice = Mice which developed lymphoma.
Non Ly mice = Mice which did not develop lymphoma.
*P < 0-01.
the four female mice which developed lymphoma had been significantly more
immunodepressed than those which did not. The occurrence ofonly two lympho-
mas among the males prevented any analysis.
Experiment 2.-The primary HA response was evaluated in C3Hf mice at
various times after the urethane treatment which was terminated at the 18th
day of age. The first group of mice was sensitized at 30 days and bled at 35
and 50 days of age; the second one was sensitized at 45 and bled at 50 and 65
days; 3 additional groups were sensitized at 90 days and bled respectively at 95,
100, 11Odays of age.
The number of animals in each group and the results are reported in Fig. 1.
At 35 days of age, the urethane-treated mice had an immunological deficit of the
primary HAresponse whichlastedforthe entire 15 days ofobservation. The same
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FIG. 1.-Primary haemagglutinin response to sheep red blood cells in C3Hf mice, either
untreated ( ) or treated with five injections ofurethane 1 mg./g. body weight from the
10th to the 18th day of age ( ). In brackets the number of animals in each
experimental group. In this and the following figures, the vertical bars indicate confidence
limit at 95%.
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behaviour was shown by mice challenged at 45 days of age and tested at 50 and
65 days. On the contrary, when immunized at 90 days of age and tested 5, 10
and 20 days later, the urethane-treated mice showed only a delay in reaching the
height of HA titre.
Experiment 3.-A group of 25 male and 31 female C3Hf mice were given five
doses of urethane 0 5 mg./g. body weight. The mice were then sensitized at 30
and 60 days ofage with SRBC and bled at 35, 50, 70 and 90 days.
The haemagglutinin titres are reported in Fig. 2. The data related to control
and to 1 mg./g. urethane-treated mice are reported from a previously published
experiment (Parmiani, et al., 1969). It appears that whereas the primaryresponse
of the animals treated with the higher dose was strongly reduced both at 35 and
at 50 days, the lower dose merely produced a delay in the primary response which
rose to control values 20 days after antigenic stimulation. The anamnestic
response was not impaired as compared with that observed in the control group,
whereas mice treated with the higher dose displayed a slight but significant reduc-
tion at 70 days only.
Only two lymphomas developed among the animals kept under observation
after the immunological tests. This low incidence prevented an analysis of a
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FIG. 2.-Primary and secondary haemagglutinin responses to sheep red blood cells in C3Hf
mice, either untreated ( ) or treated with five injections of urethane. 1 mg.fg. body
weight (- - - - -) and 0-5 mg./g. body weight (-.---).
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possible correlation between the degree of immunological impairment and the
development of leukemia.
N-nitrosomethylurea
Experiment 4.-Out of 58 newborn C3Hf mice given 50 /,g./g. body weight of
NMU 28 males and 25 females were weaned and received the antigen at 30 and
60 days of age. HA titre was determined at 35, 50, 70 and 90 days of age. A
group of 14 control mice were similarly immunized and tested. As shown in Fig.
3, both the primary and secondary immune responses were strongly depressed
in the NMU-treated mice.
Among 26 males and 18 females kept under observation after the test, 26
mice (18 males and 8 females) developed a thymic lymphoma. An attempt to
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FIG. 3.-Primary and secondary haemagglutinin responses to sheep red blood cells in C3Hf
mice, either untreated ( ) or treated with N-nitrosomethylurea 50 ug./g. body
weight at birth ( ).
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establish a correlation between degree of immunodepression and risk to develop
lymphoma was made by using two parameters, the latent period determined as the
age at the time ofkilling for lymphoma, and the tumour incidence. No correlation
could be found by plotting the HA titre at 35 days of age against the latency
(Fig. 4), since the earliest lymphomas did not occur among the most immuno-
depressed mice but rather randomly. Lack of convincing evidence for correlation
was also found when the HA titre was confronted with the incidence oflymphoma
(Table III). Moreover, no significant differences were found between the mean
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FIG. 4.-Time at death for lymphoma and primary haemagglutinin response at 35 days of age
(0 = males; 0 = females), C3Hf mice treated at birth with NM:U 50 fg./g.
TABLE III.-Relationship Between HA Titre at 35 Days and Lymphoma Incidence
in C3Hf Mice, Treated at Birth with N-nitrosomethylurea 50 ,ug./g. Body
Weight
Number of
mice with
lymphoma %
8 . 80
2 . 18
6 66
5 . 63
3 . 100
0 . 0
1 . 100
1 . 100
HA titre
(Log2)
2
3
4
5
6
7
8
9
11
Number
of mice
10
11
9
8
3
1
1
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HA titre of mice with lymphoma and those which did not develop lymphoma. In
the group with lymphoma the log2 values of the HA titre were 4-2 + 1.1 and
3-1 ± 1-2 for males and females while in the group without lymphoma the values
were 3-7 ± 1-3 and 3-7 ± 0-6 respectively.
Experiment 5. Newborn SWR mice were given NMU 25 ,ug./g. body weight
or an equivalent volume of saline. At weaning the NMU-treated mice were
divided into two groups. The first group of 11 males and 15 females received
SRBC when 31 days old; the second one, containing 16 males and 21 females was
immunized at 46 days. Twelve control mice for the first group and 19 for the
second one were immunized in the same manner. Four days later the mice
underwent splenectomy for PFC determination. As can be seen from Table IV,
there was a striking reduction ofthe number ofPFC in both NMU-treated groups.
Also NSC were clearly reduced at 35 and 50 days, whereas the reduction of spleen
weight was significant at 50 days only.
TABLE IV.-Effects of N-nitrosomethylurea 25 ag./g. Body Weight Administered
at Birth on Plaque-Forming Spleen Cells ofSWR Mice
No. of
PFC/106 nucleated
Age at Number nucleated cells/spleen Spleen weight Body weight
test of spleen cells x 106 (mg.) (g.)
Groups (days) mice (mean ± S.E.) (mean ± S.E.) (mean i S.E.) (mean ± S.E.)
Controls . 35 12 673±63 . 137±18 99±5 13-8±0-4
NMU . 26 83±13* 65±9* 83±7 10-0±0-4*
Controls 50 19 . 672±54 193±17 145±9 173±0-2
NMU . 37 162±19* . 125±9* 106±6t 16-1±0-5t
*P < Ol001.
tP < 0.005.
1 Not significant (P > 0
-01).
TABLE V.-Relationship Between Development of Thymic Lymphosarcoma and
Number of Plaque-Formning Cells in SWR Mice Treated at Birth with N-nitro-
somethylurea 25 ,ug./g. Body Weight.
Experimental Number of Age at PFC/106 N.S.C.
groups mice test (days) (mean ± S.E.)
Ly mice 12 . 35 . 90±23
Non Ly mice 5 35 . 120±44*
Ly mice . 16 50 . 100±27
Non Ly mice . 21 . 50 . 143± 19*
Ly mice = Mice which developed lymphomas.
Non ly Mice = Mice which did not develop lymphomas.
* Not significant (P > 0 -01).
As reported in Table V, the average number of PFC/106 NSC at 35 days was
not significantly different between mice which eventually developed lymphomas
and those which did not. Within the limitsofthehighimmunodepression observed
in all treated animals, a random distribution was obtained when the number of
PFC/106 NSC at 35 and 50 days was plotted against the time of lymphoma
appearance (Fig. 5).
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FIG. 5. Time at death for lymphoma and number of splenic PFC at 35 days (0 males;
0 -females) or at 50 days (- males; A = females). SWR mice treated at birth with
NMU 25 ,ug./g.
DISCUSSION
The present study confirms that urethane when injected at leukaemogenic
doses into infant mice has a strong depressive effect on the production of anti-
bodies against SRBC as detected by the number of PFC in the spleen. The
recovery of PFC formation was completed at 65 days of age, i.e. 47 days after the
last administration of the carcinogen. In a previous experiment (Parmiani et al.
1969) urethane-treated mice primed at 90 days and tested 5 days later had lower
haemagglutinin titres than controls. From the present study, however, it appears
that at 90 days there is only a delay in antibody production. The deficit in
circulating antibodies seems to persist, therefore, for approximately 50 days after
a leukaemogenic treatment with urethane to infant mice. Similarly, the cell-
mediated response evaluated as rejection time of a skin graft through weak
antigenic differences was impaired when urethane was administered to 3- or
10-day-old mice (LappeandSteinmuller, 1970; Parmiani, 1970)andthisimpairment
lasted over 60 days (Parmiani, unpublished data).
The primary HA response of animals treated with the lower dose of urethane
which had a minimal leukaemogenic action, was depressed 5 days after antigenic
stimulation but reached normal values 2 weeks later, while the secondary response
was unaffected.
A single neonatal leukaemogenic dose ofNMU caused an immunological deficit,
studied as HA titres and PFC, which was more marked, more uniformly distributed
and longer lasting than that observed in mice treated in infancy with urethane.
Also the secondaryresponse tested at 70 and 90 days ofage was strongly depressed.
Since several thymic lymphosarcomas are already well developed 10 weeks
after treatment with either urethane or NMU (Della Porta et al., 1967; Terracini
and Testa, 1970), our results show that a large portion of the latent period for
leukaemia development is affected by the lack of normal immunological response,
and this may be relevant in view ofthe fact that both urethane- and NMU-induced
lymphomas appear to have tumour-specific antigens (Della Porta et al., 1970;
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Pasternak, personal communication). Therefore, the already reported correlation
between the degree of immunodepression and the development of lymphoma
(Parmiani et al., 1969) seems well justified.
In the present experiments, however, this correlation was barely detectable
only in the group of female mice treated with the highest dose of urethane and
was not observed in the two experiments with NMU. Admittedly most of the
NMU-treated mice were strongly depressed and this may have obscured the trend
for a higher risk to develop lymphoma but it is also evident that a considerable
number of immunologically deficient animals remained free of lymphoma.
It is well known that high doses of chemical carcinogens cause severe lesions of
the haematopoietic and particularly of the lymphopoietic system (Shubik and
Della Porta, 1957; Rappaport and Baroni, 1962; Fiore-Donati and Kaye, 1964).
Therefore an investigation ofthecorrelationbetweenleukaemogenesis andimmuno-
depression must take into account that the target tissue is the same both for the
neoplastic transformation and for the impairment of immunological response and
that the likelihood of the leukaemogenic process to take place might very well be
independent ofthe degree ofthe immunological deficit. Inotherwords,thereisthe
chance that the specific, direct cytological lesion which may lead to neoplasia in
the thymus, the organ where most lymphomas arise, may have not occurred,
whereas less specific lesions ofthe lymphatic system had brought about the depres-
sion of the immunological response.
The correlation between the two phenomena may present another aspect if
one considers the hypothesis that chemical carcinogens, as well as radiation, may
induce leukaemia through activation of a latent leukaemogenic virus (Kaplan,
1967; Huebner and Todaro, 1969). Various mechanisms may be involved in
viral activation, which does not seem to be a phenomenon directly related to
immunity since not all immunodepressors appear to have oncogenic potentialities
(Della Porta et al., unpublished data). However, the immunological impairment
may play an essential role in favouring the establishment ofneoplastic cells bearing
virus-induced antigens.
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